ASP Isotopes recently released its 10-Q report. The company describes itself as a development-stage advanced materials business focused on isotope production and related services, with operations in South Africa, Hong Kong, and the United States. It is organized into two segments: Nuclear Fuels, which is developing technologies for HALEU and Lithium-6, and Specialist Isotopes and Related Services, which is working on higher-value isotopes such as C-14, Mo-100, and Si-28 for medical, industrial, and semiconductor uses.
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
ASP Isotopes said it began commercial production of enriched isotopes at both of its ASP enrichment facilities in Pretoria, South Africa during the first half of 2025, but had not generated revenue from isotope sales as of June 30, 2026. The company said its first facility is designed for light isotopes such as C-14 and C-12, while the second, larger facility is intended to handle kilogram quantities of heavier isotopes, including Si-28.
The company is targeting initial commercial shipments of enriched C-14 in the second half of 2026, depending on the timing and quality of customer feedstock. It is also targeting initial commercial shipments of Si-28 in the second half of 2026. A third enrichment facility using QE technology has completed commissioning, and ASP Isotopes is targeting initial commercial shipments of Yb-176 in the second half of 2026.
ASP Isotopes also said it has started planning additional isotope plants in South Africa and other jurisdictions, including Iceland and the United States. It identified future development targets including Zinc-68, Xenon-129/136, Germanium 70/72/74, and Chlorine-37, along with additional QE applications for Nickel-64, Gadolinium-160, Ytterbium-171, Lithium-6, and Lithium-7.
On the nuclear fuels side, QLE is pursuing uranium enrichment in South Africa. The company said it has entered into definitive agreements with TerraPower, including a term loan subject to conditions to support construction of a new uranium enrichment facility at Pelindaba, South Africa, and supply agreements for future HALEU deliveries. QLE’s South African subsidiary also signed a Pre-Implementation Services Contract with Necsa for facilities, infrastructure, utilities, and services tied to the proposed Pelindaba site.
ASP Isotopes said it has not yet applied its enrichment technologies to U-235, nor received permission or regulatory approval to conduct testing on U-235, other than the activities covered by the Necsa services contract. Its expectation that the uranium initiative could succeed is based on prior research by company scientists and the demonstrated effectiveness of QE technology on Yb-176.
The company also completed several transactions in 2026. In January, it acquired Renergen and issued 14,270,000 consideration shares. Renergen is South Africa’s onshore natural gas explorer and integrated producer of LNG and liquid helium, with its Virginia Gas Project centered on natural gas liquefaction, helium separation, and helium liquefaction. ASP Isotopes said Renergen’s principal asset is its 94.5% ownership in Tetra4, which holds the onshore petroleum production right for the project.
QLE entered into a Securities Exchange Agreement effective March 29, 2026, resulting in the deconsolidation of Skyline. QLE retained about 8.6% of Skyline’s outstanding Class A common and preferred shares after that deconsolidation.
The company said its board intends to separate the Nuclear Fuels business from the Specialist Isotopes and Related Services business into two independent companies. It said the most likely path is a listing of QLE as a separate public company, with a portion of QLE equity distributed to ASP Isotopes stockholders, though other separation options remain under review.
ASP Isotopes also detailed several operating subsidiaries and acquisitions. It owns 51% of PET Labs, a South African radiopharmaceutical company, and has an option to buy the remaining 49% for $2.2 million through January 31, 2027. It completed the acquisition of East Coast Nuclear Pharmacy in October 2025 for total consideration of $2.5 million, including $2.0 million in cash and $0.5 million in notes payable due June 30, 2026. In January 2026, it acquired 60% of Numed Diagnostics for $0.8 million and has an option to buy the remaining 40% for $0.5 million within two years.
The company said its business is being built around a mix of isotope production, radiopharmacy operations, and nuclear fuel development, with commercial shipments of key products still expected later in 2026. The market has reacted to these announcements by moving the company's shares -0.23% to a price of $4.27. If you want to know more, read the company's complete 10-Q report here.
